Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Abstract
Fluctuations in the titers of anticardiolipin antibodies (aCL) have been reported in systemic lupus erythematosus (SLE) patients, but their relation with thrombosis is not completely understood. Prospective inception cohort of 237 patients with SLE (American College of Rheumatology criteria). Positivity for antiphospholipid antibodies (aPL) was defined according to Sapporo criteria. aCL was defined as persistently positive when more than two-thirds of the determinations were positive during follow-up. Patients were classified into four groups: A [positive lupus anticoagulant (LA)], B (negative LA and persistently positive aCL), C (negative LA and transiently positive aCL) and D (negative LA and aCL). Of these 237 patients, 211 (89%) patients were women. Median age at diagnosis and follow-up were 32 (2-78) and 10 (1-31) years, respectively; 33 (13.9%), 23 (9.7%), 42 (17.7%) and 139 (58.6%) patients were classified in groups A, B, C and D, respectively. Thirty (12.6%) and 23 (9.7%) patients suffered arterial and venous thrombotic events, respectively. Adjusted risk for arterial thrombosis was increased in groups A [odds ratio (OR) 15.69, 95% confidential interval (CI) 4.79-51.42, P < 0.001] and B (OR 7.63, 95% CI 2.00-29.08, P = 0.003), but not in group C when compared with group D. Adjusted risk of venous thrombosis was increased in group A (OR 4.24, 95% CI 1.36-13.20, P = 0.013), but not in groups B or C when compared with group D. Risk of thrombosis is not increased in SLE patients with negative LA and transiently positive aCL, even fulfilling Sapporo laboratory criteria, when compared with aPL-negative SLE patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In SLE, aPL often fluctuate and are often at low or moderate titres, which still confer risk.
“However, in SLE, aPL often fluctuate and are often at low or moderate titres, which still confer risk [41–43].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [41]
Some studies reported that the increased risk of thrombosis in SLE was associated with the presence of LA and with a persistently positive aCL.
“Some studies reported that the increased risk of thrombosis in SLE was associated with the presence of LA and with a persistently positive aCL [41, 44].”
From Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus (2021) · cites this paper as [41]
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409 · see citing works
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203 · see citing works
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,581 · see citing works
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729 · see citing works
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,524 · see citing works
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
Bønaa, K. H., Njølstad, I., Ueland, P. M., Schirmer, H., Tverdal, A., Steigen, T., Wang, H., Nordrehaug, J. E., Arnesen, E., & Rasmussen, K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055227 · Cited by 1,442 · see citing works
Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Roman, M. J., Shanker, B., Davis, A., Lockshin, M. D., Sammaritano, L. R., Simantov, R., Crow, M. K., Schwartz, J. E., Paget, S. A., Devereux, R. B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035471 · Cited by 1,422 · see citing works
Brandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164 · see citing works
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993 · see citing works
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 974 · see citing works
Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus
Asanuma, Y., Oeser, A. M., Shintani, A., Turner, E. L., Olsen, N. J., Fazio, S., Linton, M. F., Raggi, P., & Stein, C. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035611 · Cited by 890 · see citing works
Harris, E. N., Gharavi, A. E., Patel, S., & Hughes, G. R. (1987) · PubMed Central · Cited by 724 · see citing works
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Aydintug, A., Jędryka-Góral, A., de Ramón, E., Fernández‐Nebro, A., et al. (1999) · Medicine · doi:10.1097/00005792-199905000-00003 · Cited by 429 · see citing works
Self-citationEffect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C. (2006) · Lupus · doi:10.1177/0961203306071872 · Cited by 411 · see citing works
Self-citationHarris, E. N. (1987) · Lara D. Veeken · doi:10.1093/rheumatology/26.5.324 · Cited by 404 · see citing works
Erkan, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.8.924 · Cited by 330 · see citing works
PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Bruce, I. N., Gladman, D. D., & Urowitz, M. B. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70138-1 · Cited by 241 · see citing works
Ruiz‐Irastorza, G., Egurbide, M.-V., Ugalde, J., & Aguirre, C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.1.77 · Cited by 238 · see citing works
Self-citationCauses of death in systemic lupus erythematosus, long‐term followup of an inception cohort
Ward, M. M., Pyun, E., & Studenski, S. A. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780381016 · Cited by 208 · see citing works
Clinical and serological features of the "anti-phospholipid syndrome" (APS)
Harris, E. N. (1987) · Lara D. Veeken · Cited by 177 · see citing works
Anticardiolipin antibodies: clinical consequences of “low titers”
SILVER, R., FLINTPORTER, T., VANLEEUWEEN, I., et al. (1996) · Obstetrics and Gynecology · doi:10.1016/0029-7844(95)00497-1 · Cited by 138 · see citing works
Systemic Lupus Erythematosus and Accelerated Atherosclerosis
Hahn, B. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038168 · Cited by 136 · see citing works
Male, C., Foulon, D., Hoogendoorn, H., Vegh, P., Silverman, E., David, M., & Mitchell, L. (2005) · Blood · doi:10.1182/blood-2005-05-2048 · Cited by 106 · see citing works
Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus.
Ishii, Y., Nagasawa, K., Mayumi, T., & Niho, Y. (1990) · Annals of the Rheumatic Diseases · doi:10.1136/ard.49.6.387 · Cited by 66 · see citing works
The Cardiovascular Burden of Lupus
Schattner, A., & Liang, M. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1507 · Cited by 59 · see citing works
Out, H. J., van Vliet, M., de Groot, P. G., & Derksen, R. H. (1992) · Annals of the Rheumatic Diseases · doi:10.1136/ard.51.3.353 · Cited by 42 · see citing works
Stroke and antiphospholipid syndrome: the treatment debate
Ruiz‐Irastorza, G., & Khamashta, M. A. (2005) · Rheumatology · doi:10.1093/rheumatology/keh666 · Cited by 30 · see citing works
Self-citationBandt, M. D., Benali, K., Guillevin, L., HACHULLA, E., Job-Deslandre, C., Fautrel, B., Fournié, G. J., Bonnet, C., Fournié, B., Le Goff, P., et al. (1999) · PubMed · Cited by 30 · see citing works
Martínez-Berriotxoa, A., Ruiz‐Irastorza, G., Egurbide, M.-V., Rueda, M., & Aguirre, C. (2004) · Lupus · doi:10.1191/0961203304lu2035oa · Cited by 26 · see citing works
Self-citationSairam, S., Baethge, B. A., & McNearney, T. A. (2003) · Clinical Rheumatology · doi:10.1007/s10067-002-0660-7 · Cited by 19 · see citing works
Wilson (1999) · doi:10.1002/1529-0131(199907)42:7
Flagged first, then by citations
Research works printed but not linked: 4
- Harris EN, 1987, Clin Exp Immunol, 68, 215
- de Bandt M., 1999, J Rheumatol, 26, 91
- Neville C., 2006, Rheumatology, 45
- Ruiz-Irastorza G., 2005, Rheumatology, 44
Cited by
Sorted by citations
Ruiz‐Irastorza, G., Crowther, M. A., Branch, W. D., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 864 · see citing works
Self-citationRuiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506 · see citing works
Self-citationDrosos, G. C., Vedder, D., Houben, E., Boekel, L., Atzeni, F., Badreh, S., Boumpas, D. T., Brodin, N., Bruce, I. N., González-Gay, M. Á., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221733 · Cited by 423 · see citing works
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356 · see citing works
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
Ruiz‐Irastorza, G., Hunt, B. J., & Khamashta, M. A. (2007) · Arthritis Care & Research · doi:10.1002/art.23109 · Cited by 324 · see citing works
Obiorah, I. E., Patel, B. A., Groarke, E. M., Wang, W., Trick, M., Ombrello, A. K., Ferrada, M. A., Wu, Z., Gutierrez‐Rodrigues, F., Lotter, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004976 · Cited by 241 · see citing works
“The increased incidence of thrombosis in immune and inflammatory diseases is multifactorial(18-24) and likely relates to activation of the coagulation cascade by cytokines and acute phase reactants as well as the presence of antiphospholipid antibodies.(19,25-27)”
BackgroundThe antiphospholipid syndrome in patients with systemic lupus erythematosus
Pons‐Estel, G., Andréoli, L., Scanzi, F., Cervera, R., & Tincani, A. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.10.004 · Cited by 203 · see citing works
“In SLE patients, an isolated, persistently positive medium-high titer aCL was associated with an increased risk of thrombotic events, while occasional positive tests were not [13,35].”
BackgroundSammaritano, L. R. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101463 · Cited by 201 · see citing works
(2019) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003072 · Cited by 147 · see citing works
The antiphospholipid syndrome: from pathophysiology to treatment
Negrini, S. M., Pappalardo, F., Murdaca, G., Indiveri, F., & Puppo, F. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0430-5 · Cited by 117 · see citing works
“LA is strongly associated with venous thrombosis and stroke, particularly in young patients, and with fetal losses beyond the 10th week of gestation [23, 101–104].”
BackgroundAntiphospholipid Syndrome during pregnancy: the state of the art.
Prima, F. A. F. D., Valenti, O., Hyseni, E., Giorgio, E., Faraci, M., Renda, E., Domenico, R. D., & Monte, S. (2011) · PubMed Central · Cited by 111 · see citing works
Cuadrado, M. J., Bertolaccini, M. L., Seed, P. T., Tektonidou, M. G., Aguirre, A., Micó, L., Gordon, C., Ruiz‐Irastorza, G., Egurbide, M.-V., Gil, A., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/ket313 · Cited by 92 · see citing works
Self-citationManagement of antiphospholipid syndrome
Tuthill, J. I., & Khamashta, M. A. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.05.002 · Cited by 78 · see citing works
Coloma Bazán, E., Donate López, C., Moreno Lozano, P., Cervera, R., & Espinosa, G. (2013) · Immunologic Research · doi:10.1007/s12026-013-8407-x · Cited by 57 · see citing works
Thrombotic manifestations of VEXAS syndrome
Groarke, E. M., Dulau‐Florea, A., & Kanthi, Y. M. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.10.006 · Cited by 55 · see citing works
Risk factors for arterial thrombosis in antiphospholipid syndrome
Matyja‐Bednarczyk, A., Swadźba, J., Iwaniec, T., Sanak, M., Dziedzina, S., Ćmiel, A., & Musiał, J. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.11.012 · Cited by 54 · see citing works
Silvariño, R., Sant, F., Espinosa, G., Pons‐Estel, G., Solé, M., Cervera, R., & Arrizabalaga, P. (2011) · Lupus · doi:10.1177/0961203310397410 · Cited by 48 · see citing works
Management of Recurrent Thrombosis in Antiphospholipid Syndrome
Nalli, C., Andréoli, L., Casu, C., & Tincani, A. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-013-0405-4 · Cited by 42 · see citing works
Bello, N., Meyers, K. J., Workman, J., Belisario, J. S. M., & Cervera, R. (2022) · Rheumatology and Therapy · doi:10.1007/s40744-022-00513-1 · Cited by 47 · see citing works
Criado-García, J., Fernandez‐Puebla, R. A., Jiménez, L. L., et al. (2008) · Revista Clínica Española · doi:10.1157/13115821 · Cited by 41 · see citing works
Hawro, T., Bogucki, A., Krupińska-Kun, M., Maurer, M., & Woźniacka, A. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119911 · Cited by 41 · see citing works
“Single antibody measurements may result in decreased specificity, leading to classify as positive also transiently positive results [61].”
BackgroundAntiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus
Demir, S., Li, J., Magder, L. S., & Petri, M. (2021) · Rheumatology · doi:10.1093/rheumatology/keaa857 · Cited by 38 · see citing works
Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome
Les, Í., Ruiz‐Irastorza, G., & Khamashta, M. A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1304720 · Cited by 38 · see citing works
Self-citationThrombosis in systemic lupus erythematosus: risk and protection
Burgos, P. I., & Alarcón, G. S. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.137 · Cited by 34 · see citing works
Espinosa, G., & Cervera, R. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2536 · Cited by 33 · see citing works
“Interestingly, LA-negative patients with persistently positive aCL (defined as positive in more than two-thirds of the determinations) had increased risk of thrombosis at the expense of arterial events, whereas in LA-negative and transiently aCL-positive patients (defined as positive on at least two occasions but on l…”
Del Ross, T., Ruffatti, A., Cuffaro, S., Tonello, M., Calligaro, A., Favaro, M., Facchinetti, M., Hoxha, A., & Punzi, L. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.08.019 · Cited by 27 · see citing works
Woo, K., Kim, K.-E., Kim, J. M., Han, J., Chung, W., & Kim, K. (2010) · Annals of Laboratory Medicine · doi:10.3343/kjlm.2010.30.1.38 · Cited by 27 · see citing works
“to establish that the risk of thrombosis increases in SLE patients with negative LAC and transiently-positive aCL [22].”
BackgroundSerological evolution in women with positive antiphospholipid antibodies
Riancho‐Zarrabeitia, L., Daroca, G., Muñoz, P., López‐Hoyos, M., Haya, A., & Martínez-Taboada, V. M. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.05.001 · Cited by 24 · see citing works
Gkrouzman, E., Sevim, E., Finik, J., Andrade, D., Pengo, V., Sciascia, S., Tektonidou, M. G., Ugarte, A., Chighizola, C. B., Belmont, H. M., et al. (2021) · The Journal of Rheumatology · doi:10.3899/jrheum.200513 · Cited by 24 · see citing works
Vitamin D and antiphospholipid syndrome: A retrospective cohort study and meta-analysis
Riancho‐Zarrabeitia, L., Cubería, M., Muñoz, P., López‐Hoyos, M., García-Canale, S., García‐Unzueta, M. T., Hernández, J. L., & Martínez-Taboada, V. M. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.10.007 · Cited by 23 · see citing works
The treatment of antiphospholipid syndrome: A harmonic contrast
Ruiz‐Irastorza, G., & Khamashta, M. A. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.10.003 · Cited by 23 · see citing works
Self-citationLoss of antiphospholipid antibody positivity post-thrombosis in SLE
Khawaja, M., Magder, L. S., GOLDMAN, D. W., & Petri, M. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000423 · Cited by 22 · see citing works
Chighizola, C. B., Pregnolato, F., ANDRADE, D. C. O. D., Tektonidou, M. G., Pengo, V., Ruiz‐Irastorza, G., Belmont, M. H., Gerosa, M., Fortin, P. R., Branch, D. W., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42459 · Cited by 22 · see citing works
Self-citationThromboprophylaxis and obstetric management of the antiphospholipid syndrome
Espinosa, G., & Cervera, R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902772302 · Cited by 16 · see citing works
“Interestingly, LA-negative patients but with persistently positive aCLs (defined as positive in more than two-thirds of the determinations) had increased risk of thrombosis at the expense of arterial events, whereas in LA-negative and transiently aCL-positive patients (defined as positive on at least two occasions, bu…”
BackgroundVenous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind
Silvariño, R., Danza, Ã., Mérola, V., Bérez, A., Méndez, E., Espinosa, G., & Cervera, R. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.05.002 · Cited by 18 · see citing works
Su, L., Qi, Z., Guan, S., Wei, L., & Zhao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978910 · Cited by 16 · see citing works
“Frontiers in Immunology 09 and with a persistently positive aCL level (36, 37).”
BackgroundManagement of antiphospholipid syndrome
Papa, N. D., & Vaso, N. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10365969 · Cited by 15 · see citing works
“The transient positivity for aCL antibodies does not increase the thrombotic risk [Martinez-Berriotxoa et al. 2007].”
BackgroundUgarte, A., de Bustos, A. G., Ruiz‐Arruza, I., Soto-Peleteiro, A., Martín‐Iglesias, D., González-Echávarri, C., & Ruiz‐Irastorza, G. (2021) · Rheumatology · doi:10.1093/rheumatology/keab307 · Cited by 13 · see citing works
Self-citationBarilaro, G., Coloma, E., Chacur, C. A., Rocca, C. D., Pérez-Isidro, A., Ruiz‐Ortiz, E., Viñas, O., Penella, D. T., Reverter, J. C., Andújar, A. M., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103208 · Cited by 13 · see citing works
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers
Chighizola, C. B., Willis, R., Maioli, G., Sciascia, S., Andréoli, L., Amengual, O., Radin, M., Gerosa, M., Atsumi, T., de Jesús, G. R., et al. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103510 · Cited by 15 · see citing works
Chen, J., Sun, S., Yan, Q., Bao, C., & Fu, Q. (2016) · Clinical Rheumatology · doi:10.1007/s10067-015-3159-8 · Cited by 12 · see citing works
“Previous studies have demonstrated that some characteristics of aPL, such as the presence of lupus anticoagulant (LAC) [6, 7], high anticardiolipin antibody (aCL) titers [8, 9], and the persistence of aPL on two or more occasions [10], were better associated with thrombotic complications in comparison with other aPL i…”
ResultGuo, Y., Dai, Y., Lai, J., et al. (2013) · Vascular · doi:10.1177/1708538113478742 · Cited by 11 · see citing works
Current management of antiphospholipid syndrome-related thrombosis
Puente, D., Pombo, G., & Forastiero, R. R. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.112 · Cited by 11 · see citing works
The Risky Business of Studying Prognosis
Lim, L. S. H., & Feldman, B. M. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.121360 · Cited by 10 · see citing works
da Rosa, G. P., Rodríguez‐Pintó, I., Cervera, R., & Espinosa, G. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1923474 · Cited by 9 · see citing works
“aCL determinations positive in the follow-up (aCL were measured on 4 or more occasions in all patients) [52].”
BackgroundQushmaq, N. A., & Al-Emadi, S. A. (2014) · ISRN Rheumatology · doi:10.1155/2014/348726 · Cited by 8 · see citing works
“The past literature review indicates that the presence of aPL along with SLE increases the risk associated with thrombosis significantly [29, 36, 37, 55, 56].”
BackgroundManagement of the antiphospholipid syndrome
Espinosa, G., & Cervera, R. (2010) · Autoimmunity Highlights · doi:10.1007/s13317-010-0004-6 · Cited by 7 · see citing works
“Interestingly, LA-negative patients but with persistently positive aCL (defined as positive in more than two-thirds of the determinations) have an increased risk of thrombosis at the expense of arterial events, whereas in LA-negative and transiently aCL-positive patients (defined as positive on at least two occasions,…”
BackgroundTreatment of Antiphospholipid Syndrome
Espinosa, G., & Cervera, R. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10055-5 · Cited by 7 · see citing works
Contraception in Kidney Disease
Sachdeva, M. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2020.05.009 · Cited by 6 · see citing works
Síndrome antifosfolipídico en el siglo xxi
Ruiz‐Irastorza, G., Martínez-Berriotxoa, A., & Egurbide, M. V. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2008.10.046 · Cited by 6 · see citing works
Self-citationMartins, F., & Campos, T. M. L. (2021) · TH Open · doi:10.1055/s-0041-1736289 · Cited by 5 · see citing works
Pathogenic Mechanisms of Thrombosis in Antiphospholipid Syndrome (APS)
Marina, P., Eleftheria, P., & Panayiotis, G. (2011) · InTech eBooks · doi:10.5772/25522 · Cited by 5 · see citing works
“After 30 years of intensive clinical and basic research, it is now well documented that LA is the strongest predictor of thrombosis [12-14].”
BackgroundLes, Í., Parraza, N., Anaut, P., Eguiluz, S., Sánchez, C., Preciado, M. E., Loza, J. Á., & Andía, A. (2017) · Rheumatology International · doi:10.1007/s00296-017-3878-z · Cited by 4 · see citing works
Management of Thrombosis in Antiphospholipid Syndrome
Khamashta, M. A., & Ruiz‐Irastorza, G. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_43 · Cited by 4 · see citing works
Self-citationClinical Management of Antiphospholipid Syndrome-Related Thrombosis
Espinosa, G., & Cervera, R. (2010) · The Open Autoimmunity Journal · Cited by 3 · see citing works
Lee, K.-Y., Cheng, C., & Chiang, Y. (2025) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2024.08.015 · Cited by 3 · see citing works
Takeshita, T., Nishimiya, N., & Hihara, Y. (2025) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2025.104442 · Cited by 2 · see citing works
González-Echávarri, C., Villar, I., Ugarte, A., Larrieta, R., & Ruiz‐Irastorza, G. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.140737 · Cited by 2 · see citing works
Self-citationHindilerden, F., Hindilerden, İ. Y., & Küçükkaya, R. D. (2017) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000538 · Cited by 2 · see citing works
Thrombosis in Rheumatological Diseases
Bashal, F. (2021) · Springer eBooks · doi:10.1007/978-981-15-8323-0_12 · Cited by 2 · see citing works
Multidisciplinary Approach in Libman–Sacks Endocarditis
Satish, V., Maliha, M., Rosenbaum, S., Modak, V., Chi, K., & Leiderman, E. (2025) · Case Reports in Cardiology · doi:10.1155/cric/5505094 · Cited by 1 · see citing works
“Among the antibodies observed in SLE and APS, lupus anticoagulant and anticardiolipin antibodies are known independent risk factors for thrombosis [4, 5].”
OBSTETRIC ANTIPHOSPHOLIPID SYNDROME - A REVIEW
Schreiber, K. I., Ateka–Barrutia, O., Khamashta, M. A., & Hughes, G. (2011) · Fetal and Maternal Medicine Review · doi:10.1017/s0965539511000131 · Cited by 1 · see citing works
Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies
Cuadrado, M. J. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00015-6 · Cited by 1 · see citing works
Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome
Ruiz‐Irastorza, G., Pengo, V., Tektonidou, M. G., Ruiz‐Arruza, I., Cuadrado, M. J., & Khamashta, M. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3194-7_11 · Cited by 1 · see citing works
Self-citationDiagnóstico del síndrome antifosfolipídico: más actores, los mismos protagonistas
Ruiz‐Irastorza, G. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2009.11.027 · Cited by 1 · see citing works
Self-citationRodríguez-Fernández, S., Ramírez, P. S., Garriga, G. E., & Segura, R. C. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)71823-5 · Cited by 1 · see citing works
Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome
Ruiz‐Irastorza, G., & Khamashta, M. A. (2009) · Technical report · doi:10.1016/s1571-5078(08)00415-7
Self-citationLe syndrome des anti-phospholipides
Ellouze, R., & Guermazi, S. (2011) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(11)71161-3
New insights into the management of antiphospholipid syndrome-related thrombosis
Puente, D., & Forastiero, R. R. (2008) · Future Rheumatology · doi:10.2217/17460816.3.1.85
Autoimmune rheumatische Erkrankungen in der Schwangerschaft
Förger, F. (2011) · Der Nephrologe · doi:10.1007/s11560-011-0526-6
Clinical Studies Examining Thrombosis Related to Autoimmune Antiphospholipid Antibodies
Bertolaccini, M. L., & Khamashta, M. A. (2010) · The Open Autoimmunity Journal
Contraception for Women with Rheumatologic Disease
Culwell, K. R., & Navarro, G. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2341-0_17
Treatment of Thrombosis in Antiphospholipid Syndrome
Ruiz‐Irastorza, G., & Khamashta, M. A. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00016-8
Self-citationMishra, R. K., Kavadichanda, C. G., Baskaran, P., et al. (2026) · Lara D. Veeken · doi:10.1093/rheumatology/keag407
Contraception for Women with Rheumatologic Disease
Culwell, K. R., & Navarro, G. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1233-9_17 · Cited by 1 · see citing works
“This risk for thromboembolism is further increased by the presence of persistently positive antiphospholipid antibodies [ 28 , 29 ].”
Background
- Authors
- Martinez-Berriotxoa, A., Ruiz-Irastorza, G., Egurbide, M.-V., Garmendia, M., Gabriel Erdozain, J., Villar, I., & Aguirre, C.
- Affiliations
- Service of Internal Medicine, Hospital de Cruces, Universidad Del Pais Vasco/Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain,
- Service of Internal Medicine, Hospital de Cruces, Universidad Del Pais Vasco/Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain
- University of the Basque Country (ES)
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2007-10
- Volume
- 16
- Issue
- 10
- Pages
- 810-816
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W1967114266
- Cited by
- 77
- References
- 32
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 7 · 2020: 4 · 2019: 2 · 2017: 4 · 2016: 5 · 2015: 2 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
- Keywords
- anticardiolipin antibodies, systemic lupus erythematosus, thrombosis, antiphospholipid antibodies, lupus anticoagulant, arterial thrombosis, venous thrombosis, Sapporo criteria
- MeSH terms
- Adolescent, Adult, Aged, Child, Female, Humans, Lupus Erythematosus, Systemic, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
